Discovery and Development

We are a biopharmaceutical company leading the discovery and development of cell specific oligonucleotides as therapeutic agents for Central Nervous System and Neuromuscular disorders

Parkinson

Preclinical data validated nLife's delivery technology for a potentially disease modifying therapy for Parkinson’s disease (PD) in rodents and non-human primates

Precision Medicine

We provide a unique oligonucleotide delivery platform with strong IP protection enabling precision medicine from “gene silencing” to “non-viral gene therapy”

Applications

Our technology can potentially be applied to a broad array of genetic disorders.

ABOUT US

We are a growing biopharmaceutical company from Spain, leading the discovery and development of cell specific oligonucleotides as therapeutic agents for Central Nervous System and Neuromuscular disorders.

FUNDING

nLife Therapeutics was established in 2010 and the investors are private Angels and three Spanish VC´s:

Crossroad Biotech, Caixa Capital Biomed and HealthEquity.

RESEARCH

We have found a way to deliver oligonucleotides to neurons and selected cell populations by means of active receptor mediated up-take, now evolving the gene silencing platform to non viral gene therapy by means of CRISPR/CAS9 RNP delivery

EARLY RECOGNITION

In 2012 Pfizer Foundation (Spain) awarded the Best Basic Research Prize to nLife based on the publication: Molecular Psychiatry. doi:10.1038/mp.2011.92: Bortolozzi, A., Castañé, A., Semakova, J., Santana, N., Alvarado, G., Cortés, R., et al. (2011). Selective siRNA-mediated suppression of 5-HT(1A) autoreceptors evokes strong anti-depressant-like effects.
In 2014 the Michael Jay Fox Foundation awarded nLife with a grant to support the characterization of the compound NLF-PD-1233 against alpha-synuclein as novel disease modifying treatment for Parkinson’s disease.